key: cord-0936124-5ws439or authors: Villar, Juan Carlos; Gumisiriza, Nolbert; Abreu, Lucas Guimarães; Maude, Richard J; Colebunders, Robert title: Defining post-COVID condition date: 2022-02-23 journal: Lancet Infect Dis DOI: 10.1016/s1473-3099(22)00060-3 sha: 9b1a2c6d8e61391d53c83e9eacb6ca7d098ccaca doc_id: 936124 cord_uid: 5ws439or nan definition proposed by this working group. There are some compelling reasons supporting this perspective. A post-COVID-19 condition can affect people who have only minor, nonspecific or even no symptoms during the acute phase of the infection. Such cases are not regularly tested for SARS-CoV-2. Additionally, there has been inadequate access to testing in low-income and middle-income countries (LMICs). People also avoid testing for fear of the consequences of a positive result. Furthermore, if done late, tests can become negative, making a retrospective diagnosis unfeasible. Although a clinical definition without laboratory confirmation increases sensitivity (allowing more affected people to receive care), it comes with a trade-off with specificity. Hence, a stricter definition might be required for research purposes and comparison between different settings. The WHO Delphi exercise had relatively few participants from Africa, South America, and southeast Asia. Although we cannot say that having a more global presence would have changed the definition, this underrepresentation of LMICs might be associated with the lack of ongoing research about this condition in low-income countries. We suggest that such research is urgently needed. For example, the COVID-19 pandemic caused an unprecedented amount of stress for people in LMICs. 4 Still, the full scale of mental health issues related to post-COVID-19 condition remains undetermined. One of the criteria in the proposed definition is that "symptoms cannot be explained by an alternative diagnosis". Fulfilling the criterion might also be difficult in LMICs, where additional diagnostic testing might not always be available. Here, once again, health services might need to move on with diagnostic criteria, while rigorous studies inform and refine future definitions. trials and to support ongoing trials. Flexibilities include the possibility for remote monitoring and verification, and direct shipment of investigational medicines to patients. The EMA emergency task force (ETF) was activated early in the COVID-19 pandemic. In addition to being responsible for the rolling review of marketing authorisation applications for COVID-19 vaccines and therapeutics, the ETF also provides expedited scientific advice free of charge for COVID-19 trials. In early 2022, the competence of EMA ETF will be extended 5 to include support for cooperation between sponsors to enable large-scale platform trials in public health emergencies. As part of the global effort to deliver more effective clinical trials, European regulators are contributors to the ongoing revision of the International Conference on Harmonisation Good Clinical Practice and support the work within the International Coalition of Medicines Regulatory Authorities to facilitate the international acceptability of large-scale platform trials. In January, 2022, the European Commission, EMA, and HMA launched ACT EU to transform how clinical trials are run. 6 Under ACT EU, we commit to modernise clinical trial methods and oversight and bring together the clinical research stakeholder community through a series of multi-stakeholder workshops that will focus on enabling more effective clinical trials involving researchers across Europe, benefitting from the EU's rich biomedical research potential. Working together, we believe we can invigorate the clinical trials environment in the EU for the benefit of patients and to improve knowledge and innovation. We declare no competing interests. Joan B Soriano and colleagues 1 proposed a clinical case definition for post-COVID-19 condition. We thank this WHO-led working group for their efforts to provide an operational definition for this emerging, challenging condition. Similar to previous statements by the Centers for Disease Control and Prevention 2 and the National Institute for Health and Care Excellence, 3 the criterion "SARS-CoV-2 laboratory confirmation" was not included in the working group of the COVID-19 Clinical Research Coalition, 5 we advocate for more and better research on post-COVID-19 condition originating in LMICs, including people with a history of laboratory-confirmed COVID-19 and where relevant, suitable matched controls to keep learning from comparison, building capacity to tackle future challenges on these and other common challenges and inform on the health care of our patients. COVID-19 rapid guideline: managing the long-term effects of COVID-19 COVID-19 mental health impact and responses in low-income and middle-income countries: reimagining global mental health COVID-19 Clinical Research Coalition. Clinical epidemiology working group We declare no competing interests.